Press "Enter" to skip to content

GSK’s Dovato meets primary goal in late-stage HIV study

The company’s HIV drugs division ViiV said the late stage study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults who switched to the regimen from at least a triple combination TAF-containing treatment.

Original source:

Also Read:   Moderna, Switzerland's Lonza strike deal on potential COVID-19 vaccine